Ashling Wahner

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.

Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.

Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.

The FDA has approved zenocutuzumab for the treatment of adult patients with NRG1 fusion–positive advanced, unresectable, or metastatic CCA.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

Treatment with gedatolisib-based regimens led to significant PFS benefits vs alpelisib/fulvestrant in PIK3CA-mutant HR-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from April 2026, including an ODAC decision and a breakthrough device designation.

Alan L. Ho, MD, PhD, discusses the unique elements of Oz-V that may contribute to its efficacy and tolerability in OPSCC.

Oncology experts share perspectives and suggest advice for reducing burnout related to conference attendance and taking personal time away from the clinic.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Frontline treatment with zovegalisib, atirmociclib, and fulvestrant yielded responses in pretreated, PI3Kα-mutated HR-positive metastatic breast cancer.

Breast cancer experts discuss nuances of using CDK4/6 inhibitors to treat patients with high-risk hormone receptor–positive, HER2-negative early disease.

Rena D. Callahan, MD, discusses clinical considerations for CDK4/6 inhibitor–based regimens and oral SERDs in hormone receptor–positive breast cancer.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

With burnout and conference attendance prevalent across the oncology community, oncology professionals strive to enact positive changes.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.